|Bid||2.0000 x 3100|
|Ask||2.0100 x 21500|
|Day's range||1.8400 - 2.0000|
|52-week range||0.7500 - 2.4000|
|Beta (5Y monthly)||1.66|
|PE ratio (TTM)||N/A|
|Earnings date||06 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.00|
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, to be hosted in a virtual format, on Monday, September 14, 2020 at 2:30 p.m. ET.
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common stock as inducements to four newly-hired employees in connection with commencement of employment with the Company.